The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia

BACKGROUND: Sofosbuvir and ledipasvir-sofosbuvir are both newer direct-acting antiviral agents for the treatment of hepatitis C. The high list prices for both drugs have led to concern about the budget impact for public drug coverage programs. Therefore, we studied the impact of public prescription...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Harriet, Janjua, Naveed Z., McGrail, Kimberlyn M., Harrison, Mark, Law, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920374/
https://www.ncbi.nlm.nih.gov/pubmed/33647068
http://dx.doi.org/10.1371/journal.pone.0247843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920374/
https://www.ncbi.nlm.nih.gov/pubmed/33647068
http://dx.doi.org/10.1371/journal.pone.0247843

Ejemplares similares